B2, key topic 5 - Medicine, surgery, health and the NHS, 1920–48

Fleming And Penicillin

Alexander Fleming's discovery in 1928 is one of the most famous accidents in medical history, but it only makes sense if you separate discovery from development.

Fleming was working at St Mary's Hospital in London. When he returned from holiday, he noticed mould growing on a plate of Staphylococcus bacteria. Around the mould, the bacteria had not grown. Fleming realised that the mould was producing a substance that could kill or stop bacteria. He called it penicillin.

That mattered because bacterial infection was still a major danger. Before antibiotics, a small cut, childbirth, pneumonia, infected wounds after surgery or a battlefield injury could become fatal. Penicillin suggested a new kind of treatment: a drug that could attack bacteria inside the body without the same danger as older chemical treatments.

However, Fleming did not turn penicillin into a usable mass treatment. He published his findings in 1929, but other scientists showed little interest. He could not purify enough of the substance for reliable treatment, and penicillin was unstable and difficult to produce. For several years it looked like a laboratory curiosity rather than a medical revolution.

This is a useful example of historical significance. Fleming was significant because he identified the antibacterial effect and named the substance. But the later breakthrough depended on other scientists solving practical problems that Fleming had not solved.

Misconception check: do not write that Fleming "invented antibiotics" in a simple single-step way. A better answer is that he discovered penicillin's antibacterial effect, but its use as a medicine required further development.

Florey, Chain and production

The development of penicillin depended on Howard Florey, Ernst Chain and the Oxford team. In the late 1930s, they returned to Fleming's earlier research and treated penicillin as a serious scientific problem: could it be purified, tested and produced in enough quantity to treat infection?

Chain helped with the biochemical work needed to extract and purify penicillin. Florey organised the research team, experiments and clinical direction. Other members of the Oxford project also mattered, including Norman Heatley, who helped design practical equipment for growing and extracting penicillin, and women workers who tended the fermenting broth in the laboratory. The specification names Fleming, Florey and Chain, but the development was still a team process.

In 1940, the Oxford team infected eight mice with a deadly bacterial infection. The four mice given penicillin survived; the four without it died. This was powerful evidence that penicillin could work inside a living body, not just in a petri dish.

Human treatment proved both exciting and frustrating. In 1941, Albert Alexander, a policeman with a severe infection, improved after receiving penicillin, but the supply ran out and he died. The case showed both the promise of penicillin and the production problem. A treatment that exists only in tiny quantities cannot transform public health.

The Second World War then helped turn a scientific breakthrough into mass production. British industry was under wartime pressure, so Florey took the work to the United States in 1941. At Peoria, researchers and pharmaceutical companies improved fermentation methods and yields. Wartime demand made governments and industry treat penicillin as urgent. Penicillin reached military patients in 1943, but supplies were still limited. Production expanded greatly in 1944, providing substantial supplies for Allied casualties by D-Day. In 1945, Fleming, Florey and Chain shared the Nobel Prize in Physiology or Medicine.

Penicillin changed treatment because it made previously dangerous bacterial infections much more treatable. It also changed surgery. Operations became safer when post-operative infection could be treated more effectively. That does not mean infection disappeared, but the risk balance shifted.

Wartime Surgery And Transfusion

War is destructive, but it can accelerate medical change because it creates urgent, large-scale problems. The Second World War produced severe burns, blast injuries, crush injuries and mass civilian and military casualties. Doctors and governments had to organise treatment at a scale that peacetime medicine had not demanded.

Skin grafts and reconstructive surgery were especially important for burned aircrew. Pilots and bomber crews could suffer deep burns when aircraft caught fire. At Queen Victoria Hospital, East Grinstead, Archibald McIndoe worked with Allied aircrew who had been badly burned or crushed. He developed and refined plastic and reconstructive surgery, including techniques for restoring damaged skin and tissue. His work also stressed rehabilitation: patients needed psychological recovery, confidence and social reintegration, not only an operation.

Skin grafting means moving healthy skin to cover damaged areas. In severe burns, this could protect wounds, help healing and reduce disfigurement. The war did not invent all skin grafting; earlier surgeons had already developed important plastic surgery techniques. The Second World War made the work more systematic and urgent because the injuries were numerous and severe.

Blood transfusion was another area where war made scale and organisation crucial. The science of blood groups and storage had been developing before 1939. During the Second World War, Britain needed blood for injured civilians and service personnel on a much larger scale. Blood donation centres and blood banks helped ensure blood was available when casualties arrived. In 1946, the Ministry of Health took control of blood banks and created the National Blood Transfusion Service, showing how wartime organisation fed into postwar public health.

For Paper 2, Section B, the key phrase is "importance of the Second World War". It was important because it increased demand, concentrated expertise, encouraged government organisation and made new methods worth investing in quickly.